Oncopeptides AB
STO:ONCO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (41.2), the stock would be worth kr7.21 (453% upside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 7.4 | kr1.3 |
0%
|
| 3-Year Average | 41.2 | kr7.21 |
+453%
|
| 5-Year Average | 42 | kr7.36 |
+464%
|
| Industry Average | 7.9 | kr1.38 |
+6%
|
| Country Average | 2 | kr0.35 |
-73%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
kr653.7m
|
/ |
Jan 2026
kr71.1m
|
= |
|
|
kr653.7m
|
/ |
Dec 2026
kr187.7m
|
= |
|
|
kr653.7m
|
/ |
Dec 2027
kr301.9m
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| SE |
|
Oncopeptides AB
STO:ONCO
|
505.8m SEK | 7.4 | -2.1 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
373.6B USD | 6.1 | 89.2 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
186.6B USD | 5.1 | 24.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
162.4B USD | 5.5 | 19.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.6B USD | 9 | 27.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
74.7B USD | 5.2 | 16.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.3B EUR | 11.6 | 37.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60B AUD | 2.7 | 29.6 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 1.2 |
| Median | 2 |
| 70th Percentile | 4.4 |
| Max | 13 940.4 |
Other Multiples
Oncopeptides AB
Glance View
Oncopeptides AB is a pharmaceutical company focused on the development of targeted therapies for hematological diseases. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2017-02-22. The Company’s lead product candidate PEPAXTO (melphalan flufenamide, also known as melflufen) has been approved in relapsed or refractory multiple myeloma by The U.S. Food and Drug Administration. Melphalan flufenamide is the first drug originated from the Company PDC-platform and is evaluated in a clinical study program, including the ongoing phase 3 OCEAN study. Melphalan flufenamide is an anticancer peptide-drug conjugate for patients with relapsed or refractory multiple myeloma. The drug uses technology that links a peptide carrier to a cytotoxic agent, resulting in a lipophilic compound. Due to its high lipophilicity, it is distributed into the cells. Melphalan flufenamide is designed to leverage aminopeptidases, enzymes which are overexpressed in myeloma cells and cause the release of the cytotoxic agents in the cells.
